Claims
- 1. A compound of the formula ##STR89## or a physiologically acceptable salt or an optical isomer thereof, wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl containing 1-6 carbon atoms, cycloalkyl containing 3-6 carbon atoms, cycloalkyl-alkyl containing 4-6 carbon atoms, 1-adamantyl, 2-adamantyl and benzyl; R.sub.2 is hydrogen and R.sub.3 is selected from the group consisting of hydrogen and benzyl, provided that when R.sub.3 is H, then R.sub.1 is alkyl, cycloalkyl, cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl or benzyl, or a physiological acceptable salt or an optical isomer thereof.
- 2. A compound according to claim 1, wherein R.sub.1 is CH.sub.3 and R.sub.3 is H.
- 3. A compound according to claim 1 wherein R.sub.2 and R.sub.3 are H and R.sub.1 is selected from the group consisting of 1-adamantyl and 2-adamantyl.
- 4. A compound of the formula ##STR90## or a physiologically acceptable salt or an optical isomer thereof, wherein R.sub.1 is hydrogen, R.sub.2 is 1-adamantyl and R.sub.3 is hydrogen.
- 5. A compound according to claims 3, 4, 1 or 2 in the form of its sodium salt.
- 6. A pharmaceutical preparation comprising an active ingredient in an amount effective to treat a virus infection in an animal or man, together with a physiologically acceptable carrier, said active ingredient being a compound of the formula ##STR91## wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl containing 1-6 carbon atoms, cycloalkyl containing 3-6 carbon atoms, cycloalkyl-alkyl containing 4-6 carbon atoms, 1-adamantyl, 2-adamantyl and benzyl; R.sub.2 is hydrogen and R.sub.3 is selected from the group containing hydrogen and benzyl, provided that when R.sub.3 is H, then R.sub.1 is alkyl, cycloalkyl or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl or benzyl, or a physiological acceptable salt or an optical isomer thereof.
- 7. A pharmaceutical preparation according to claim 6 wherein, in the compound of the formula I, the radicals R.sub.1 and R.sub.2 are hydrogen and R.sub.3 is benzyl.
- 8. A pharmaceutical preparation according to claims 7 or 6, wherein the active substance is in the form of its sodium salt.
- 9. A pharmaceutical preparation according to claims 7 or 6 in dosage unit form.
- 10. A pharmaceutical preparation according to claims 7 or 6 formulated for systemic administration.
Priority Claims (8)
Number |
Date |
Country |
Kind |
53580/77 |
Dec 1977 |
GBX |
|
53581/77 |
Dec 1977 |
GBX |
|
53582/77 |
Dec 1977 |
GBX |
|
53583/77 |
Dec 1977 |
GBX |
|
28548/78 |
Jul 1978 |
GBX |
|
28552/78 |
Jul 1978 |
GBX |
|
28553/78 |
Jul 1978 |
GBX |
|
28555/78 |
Jul 1978 |
GBX |
|
Parent Case Info
This application is a continuation-in-part of Ser. No. 971,896, filed Dec. 21, 1978, now abandoned.
US Referenced Citations (5)
Number |
Name |
Date |
Kind |
3767795 |
Schleicher et al. |
Oct 1973 |
|
3943201 |
McIntosh |
Mar 1976 |
|
4052439 |
Herrin et al. |
Oct 1977 |
|
4092412 |
Maod et al. |
May 1978 |
|
4215113 |
Eriksson et al. |
Jul 1980 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
7425333 |
Feb 1975 |
FRX |
Non-Patent Literature Citations (3)
Entry |
Helgstrand, et al. "Science" vol. 201, (1978) 819-821. |
Shipkowitz, et al. "Applied Microbiology" Sep. 1973, pp. 264-267. |
Unlisted Drugs, vol. 17, (1965) (No. 12), HC 8020 (m), p. 89. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
971896 |
Dec 1978 |
|